Schweinfurthins: novel treatment for breast cancer
Schweinfurthins: novel treatment for breast cancer
批准号:
7798657
负责人:
JEFFREY D NEIGHBORS
金额:
$20.4万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-11 至 2012-07-31
关键词:
AddressAdvocateAmerican Cancer SocietyAntitumor Drug Screening AssaysBiological AssayBiological FactorsBreastBreast Cancer CellBreast Cancer TreatmentCancer cell lineCell LineCentral Nervous System MelanomaCessation of lifeCollaborationsDataDevelopmentDiseaseEvaluationFamilyFundingGoalsGrantGrowthHumanIn VitroIowaKidneyLegal patentMedicalModelingNational Cancer InstituteOutcomePatientsPharmaceutical PreparationsPhaseResearchSmall Business Innovation Research GrantSourceSurvival RateTerpenesTestingTherapeuticTumor Cell LineUniversitiesWomanWorkXenograft Modelanalogcancer typedesignexperienceimprovedin vitro activityin vivoinnovationleukemia/lymphomamalignant breast neoplasmnovelpublic health relevance
中文摘要
描述(由申请人提供):据美国癌症协会估计,2008年美国发生了182,000例浸润性乳腺癌,其中40,000例死于乳腺癌。在患有转移性乳腺癌的女性中,5年生存率为27%。在SBIR I期申请中提出的研究旨在评估开发用于治疗乳腺癌的合成schweinfurthins的可行性。国家癌症研究所的工作人员从一个天然产品家族中分离出了第一批schweinfurthins,并在NCI 60细胞系生物测定中显示出对乳腺癌、白血病/淋巴瘤、肾脏、黑色素瘤和中枢神经系统亚组的显著活性。schweinfurthins似乎具有一种新的作用机制,可以广泛适用于解决乳腺癌患者未满足的重大医疗需求。虽然最初是在天然产物筛选过程中发现的,但这些化合物的天然来源仅提供少量,并且已被证明不可靠。Terpenoid Therapeutics及其在爱荷华大学的合作者已经设计并合成了超过50种schweinfurin类似物,其中包括几种在体外对人类乳腺癌细胞系具有低纳摩尔效力的化合物。本I期可行性应用的目标是在人乳腺癌异种移植模型中建立合成施魏因芬素的体内疗效。本项目将通过两个具体目标来进一步开发用于治疗乳腺癌的合成施魏因富素:1)分析单独使用和与目前用于治疗乳腺癌的药物联合使用的合成施魏因富素对人乳腺癌细胞系的体外生长抑制作用,并选择化合物进行体内疗效模型测试;2)在乳腺癌异种移植模型中单独或联合标准治疗方法测试合成施魏英酮,以确定体内疗效。这些研究的数据将支持II期SBIR提案,将合成schweinfurin推进到ind研究中。
英文摘要
DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 182,000 cases of invasive breast cancer occurred in the US in 2008, with 40,000 deaths due to breast cancer. Among women with metastatic breast cancer, the 5-year survival rate is 27%. The studies proposed in this SBIR phase I application are designed to assess the feasibility of developing synthetic schweinfurthins for the treatment of breast cancer. The first schweinfurthins from a family of natural products were isolated by workers at the National Cancer Institute and showed remarkable activity against the breast, leukemia/lymphoma, renal, melanoma and CNS sub-panels of the NCI 60-cell line bioassay. The schweinfurthins appear to have a novel mechanism of action and could have broad applicability to address the significant unmet medical need of patients with breast cancer. While initially discovered during a natural products screen, the natural sources of these compounds supply only small amounts and have proven unreliable for re-isolation. Terpenoid Therapeutics and its collaborators at the University of Iowa have designed and synthesized over fifty schweinfurthin analogues, including several compounds which have low nanomolar potency against human breast cancer cell lines in vitro. The goal of this phase I feasibility application is to establish in vivo efficacy of synthetic schweinfurthins in human breast cancer xenograft models. This project will undertake the further development of synthetic schweinfurthins for the treatment of breast cancer through two specific aims: 1) Analyze synthetic schweinfurthins alone and in combination with drugs currently used in the treatment of breast cancer for in vitro growth inhibition of human breast cancer cell lines and select compounds for testing in in vivo efficacy models; and 2) Test a synthetic schweinfurthin alone and in combination with standard therapies in breast cancer xenograft models to establish in vivo efficacy. The data from these studies will support a Phase II SBIR proposal to advance a synthetic schweinfurthin into IND-enabling studies.
PUBLIC HEALTH RELEVANCE: In spite of important advances in the treatment of metastatic breast cancer, there remains a need for innovative new therapies. According to the American Cancer Society an estimated 182,000 cases of invasive breast cancer occurred in the US in 2008, with 40,000 deaths due to breast cancer. Among women with metastatic breast cancer, the 5-year survival rate is 27%. Research to identify novel treatments for metastatic breast cancer, such as the synthetic schweinfurthins, is needed to improve the outcomes for patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Feasibility study of GGDPS inhibition for osteoporosis
-
批准号:8522844
-
项目类别:
-
资助金额:$16.31万
-
财政年份:2013
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Pawhuskins: Potential Treatments for Stimulant Abuse.
-
批准号:7842616
-
项目类别:
-
资助金额:$22.03万
-
财政年份:2009
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Pawhuskins: Potential Treatments for Stimulant Abuse.
-
批准号:7638987
-
项目类别:
-
资助金额:$19.81万
-
财政年份:2009
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Improving the Distribution of Geranylgeranyl Diphosphate synthase inhibitors.
-
批准号:7608986
-
项目类别:
-
资助金额:$11.5万
-
财政年份:2009
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Preclinical Development of Geranylgeranyl Disphosphate Synthase Inhibitors as Ant
-
批准号:7325831
-
项目类别:
-
资助金额:$12.31万
-
财政年份:2007
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Developing Schweinfurthin Analogs as Glioma Therapies
-
批准号:8055678
-
项目类别:
-
资助金额:$11.25万
-
财政年份:2007
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Novel Glioblastoma Therapeutics
-
批准号:7218415
-
项目类别:
-
资助金额:$10.99万
-
财政年份:2007
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
Developing Schweinfurthin Analogs as Glioma Therapies
-
批准号:7668303
-
项目类别:
-
资助金额:$33.15万
-
财政年份:2007
-
负责人:JEFFREY D NEIGHBORS
-
依托单位:
海外基金